{"id":"NCT01102413","sponsor":"Pharmacosmos A/S","briefTitle":"Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia","officialTitle":"A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2010-04-13","resultsPosted":"2015-12-03","lastUpdate":"2015-12-03"},"enrollment":351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia","Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Monofer","otherNames":[]},{"type":"DRUG","name":"Iron Sulphate","otherNames":[]}],"arms":[{"label":"Monofer","type":"EXPERIMENTAL"},{"label":"Iron Sulphate","type":"ACTIVE_COMPARATOR"}],"summary":"The study is designed to determine the effects of an investigational drug Monofer in subjects with non-dialysis dependent chronic kidney disease (NDD-CKD) subjects and with iron deficiency anaemia (IDA).","primaryOutcome":{"measure":"Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.","timeFrame":"Baseline, 4 weeks","effectByArm":[{"arm":"Monofer","deltaMin":0.57,"sd":null},{"arm":"Iron Sulphate","deltaMin":0.35,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Denmark"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":228},"commonTop":["Pyrexia","Nasopharyngitis","Diarrhoea","Hypertension","Vomiting"]}}